NCT04905043 - A Study to Evaluate the Effect of Gastric pH on Acalabrutinib Pharmacokinetics (PK) in Healthy Adult Participants | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 3, 2016

Primary Completion Date

July 11, 2016

Study Completion Date

July 11, 2016

Conditions

Healthy Volunteers

Interventions

DRUG

Acalabrutinib

Participants will receive a single oral dose of acalabrutinib 100 mg capsule on Day 1 (Period 1) and Day 4 (Period 2).

DRUG

SmartPill®

Participnats will receive a single oral dose of wireless motility/pH capsule (SmartPill®) on Day 1 (Period 1) and Day 4 (Period 2).

Trial Locations (1)

Celerion, Tempe